location-svg
Meine Position
Download
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
eBook
eBook
Fachbuch
2019

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Bewertung abgeben
Autor/-in
ISBN
EAN
978-3-030-13754-0
9783030137540
Artikel-Nr.
G4WPGYD
Rabatt
-21.8
%
CHF 177.00
CHF
138.50
Anzahl
1
speech-bubble-svg Beschreibung

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry.  And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products.  These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the CMC strategy and regulatory compliance requirements for these challenging products.  Companies clearly plan out the strategy for their clinical study plans, but frequently, the development of a strategy for CMC is an afterthought. Coupled with the complexity of the biopharmaceutical manufacturing processes and products, and this can be a recipe for disaster. The third edition of this book provides insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for all biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and genetically engineered human cells) from early clinical stage development through market approval.  The third edition of this book provides added coverage for the biosimilars, antibody drug conjugates (ADCs), bispecific antibodies, genetically engineered viruses, and genetically engineered cells. This third edition of the book also addresses the heightened pressure on CMC regulatory compliance timelines due to the introduction of expedited clinical pathways moving the clinical development closer to a seamless phase process (e.g., FDA Breakthrough Therapy designation, CBER Regenerative Medicine Advanced Therapy (RMAT) designation, EMA Priority Medicines (PRIME) designation). The Challenge of CMC Regulatory Compliance for Biopharmaceuticals is essential, practical information for all pharmaceutical development scientists, Manufacturing and Quality Unit staff, Regulatory Affairs personnel, and senior management involved in the manufacture of biopharmaceuticals.

feather-svg
Stichwörter
Inhaltsverzeichnis

Complexity of Biologics CMC Regulation.- Biopharmaceutics are Not Chemical Drugs.- An Effective CMC Strategy is Possible.- Challenge of Adventitious Agent Control.- Biopharmaceutical Source Materials.- Manufacturing of  Biopharmaceutical APIs.- Manufacturing of the Drug Product.- Complex Process-Related Impurity Profiles.- Product Characterization is a Journey.- Priceless Potency (Therapeutic Activity).- Quality Attributes of a Biopharmaceutical.- Designing the Stability Program.- The Art of Setting Specifications.- Demonstrating Product Comparability After Process Changes.- Invaluable CMC-Focused Meetings with Regulatory Authorities.

feather-svg
Autor/-in
Autor/-in
Publikation
Schweiz
3. Auflage -
08.05.2019
Springer Verlag
speech-bubble-svg
Sprache
Englisch
book-svg Format
eBook
PDF
426 Seiten
star-svg
Bewertungen
credit-card-svg Zahlungsarten
payment-einzahlungsschein payment-twint payment-mastercard payment-visa payment-american-express payment-post-finance payment-e-post-finance payment-apple-pay payment-google-pay samsung-pay
Bestellen Sie einfach auf Rechnung oder bezahlen Sie bequem und gebührenfrei mit Twint, Kreditkarte, PostFinance, Apple, Google oder Samsung Pay.
Rückgabe
Kein Rückgaberecht
Bei diesem eBook hat entweder der Verlag (Hersteller) das Rückgaberecht ausgeschlossen oder eine Rückgabe ist aufgrund des Vertriebssystems nicht möglich.
eldar-store-white-svg
S
SPIEGEL Bestseller